Heterogeneity and Responder Phenotype of Anti-Inflammatory Response to Low-Dose Colchicine in Chronic Coronary Syndrome: A Single-Center Retrospective Study
This single-center retrospective study of 442 chronic coronary syndrome patients reveals that while low-dose colchicine induces substantial heterogeneity in C-reactive protein responses, baseline blood-count-derived indices and clinical characteristics fail to reliably identify anti-inflammatory responders, particularly when accounting for biological variation.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine your body is a bustling city. Usually, the police (your immune system) keep things calm, but sometimes they get a little too excited and start patrolling the streets with unnecessary flare, causing a low-level, smoky inflammation. In people with chronic coronary syndrome, this "smoke" lingers around the heart's arteries, increasing the risk of a traffic jam (a heart attack) even when the roads are otherwise clear. Scientists have long suspected that putting out this smoke is just as important as fixing the roads. Enter colchicine, an old, cheap medicine that acts like a fire extinguisher for this specific type of inflammation. Doctors have started prescribing it to calm things down, hoping it will stop heart attacks. But here's the tricky part: just because you hand out fire extinguishers doesn't mean every building needs one, or that every extinguisher works the same way on every fire. Some people's bodies might be super-sensitive to the spray, while others might not react at all. The big question is: Can we tell who is actually getting the smoke cleared out just by looking at a simple blood test, or do we need a fancy, expensive lab machine? And can we predict who will be a "good responder" before we even start the treatment?
This study, conducted by researchers at the Affiliated Hospital of Guangdong Medical University, dives right into that mystery. They looked at 442 patients with chronic coronary syndrome who were taking a low dose of colchicine (0.5 mg per day). The team wanted to see two main things: first, how much did the "smoke" (measured by a protein called C-reactive protein, or CRP) actually go down in different people? And second, could they use a cheap, easy blood test (counting white blood cells and platelets) to predict who would be a "responder" (someone whose inflammation dropped significantly) instead of using the more expensive CRP test?
The results were a bit of a reality check. When the researchers looked at the data, they found that the inflammation did drop on average. About half of the patients (51.1%) showed a drop in CRP of at least 30%, which is the standard rule of thumb for saying, "Hey, this person is responding!" However, when the scientists applied a stricter, more scientific rule that accounts for natural biological noise and measurement errors (called the "reliable change index"), the picture changed dramatically. Suddenly, only 15.6% of the patients showed a drop big enough to be sure it wasn't just random fluctuation. That's a huge gap in how we classify the change: the "standard" count said half the people were helped, but the "strict" count said only about one in six showed a change beyond what we'd expect from normal biological noise. The difference between these two numbers was 35.5 percentage points, and the researchers noted that this gap could swing wildly depending on how you calculate the natural noise in the body. Crucially, because the study didn't track how long patients actually took the medicine or if they stuck to the schedule, these findings describe patterns of CRP change rather than confirmed proof that the drug provided a pharmacological benefit to those specific individuals.
The team also tried to find a "responder phenotype"—a specific profile of a patient that would predict they would be a responder. They built a model using things like age, gender, kidney function, and other health factors. They found that the single strongest predictor was simply how high the CRP was before the treatment started. People with higher starting inflammation were more likely to show a big drop. However, once they accounted for the math trick where a high starting number makes a big drop easier to calculate, none of the other factors (like having diabetes or kidney disease) remained statistically significant. The model they built was okay at guessing, but it wasn't a magic crystal ball.
Finally, they tested the "cheap blood test" idea. They looked at ratios like the neutrophil-to-lymphocyte ratio (NLR) and others that can be calculated from a standard blood count for free. They hoped these would act as a cheap substitute for the CRP test. The answer? Not really. These blood-count indices performed almost no better than flipping a coin (with accuracy scores between 0.55 and 0.59, where 0.5 is pure chance). They couldn't reliably tell who was a responder and who wasn't.
In short, the study suggests that while colchicine is associated with lower inflammation on average, the response is highly variable from person to person. The "standard" way of counting responders might be overestimating how many people show a true, reliable change in their CRP levels. Furthermore, we can't just use a cheap blood count to predict who will respond; we still need the specific CRP test, and even then, a single test might not be enough to be certain. The researchers conclude that we need to be careful about declaring someone a "responder" based on just one measurement, and we definitely can't replace the CRP test with a simple blood cell count just yet. It's a reminder that biology is messy, and what looks like a clear signal on paper might just be the static of a noisy signal.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.